Buying level for Sun Pharmaceuticals

Sun Pharmaceuticals (daily intraday chart)

Sun Pharma

Sun Pharmaceuticals have INTERNAL employee’s problem and management system, but it will be solved in 2-3 days…. Investors and Few Big Profile people eying on this stock for buy 789-809 (Internal New) Targets 934-978 and in two months 1000-1100. Support is given in chart.

To become a subscriber, subscribe to our free newsletter services. Our service is free for all.

Continue reading

The arrow hit the target – VEDL

47149047.cms

The target has been achieved yesterday. We had given the call to buy Vedanta limited. In between 194 and 195

and we had given the target 202 to 205, which we reached yesterday.

To become a subscriber, subscribe to our free newsletter services. Our service is free for all.

Continue reading

Buy Buy Buy!!! Vedanta Limited

Vedanta Limited. (daily intraday chart)

Vedanta Limited

Buying opportunity for Vedanta Limited. Get ready to fire the bullet, we already updated the buying level for our subscribers.

To become a subscriber, subscribe to our free newsletter services. Our service is free for all.

Continue reading

CNX Nifty Resistance on it’s way!

CNX Nifty (daily intraday chart)CNX Nifty 21st MayCNX Nifty Resistance is about to come, hold on your seat belt tightly.

To become a subscriber, subscribe to our free newsletter services. Our service is free for all.

Continue reading

CNX NIFTY updated 11th May 2015

CNX NIFTY Updated Daily Chart : 11th May 2015

nifty cnx

Exactly, I stated in last update about fall of Nifty: Click here

More Detail will be for Subscribers, if time permit I will update here for you.

To become a subscriber, subscribe to our free newsletter services. Our service is free for all.

Continue reading

Buying Opportunity For L&T Book Profit

Larsen & Toubro Ltd.(daily intraday chart)

L & T Ltd.Buying opportunity of Larsen & Toubro ltd. is here, grab this opportunity and book profit

To become a subscriber, subscribe to our free newsletter services. Our service is free for all.

Continue reading